Herbert Tilg

Appearances

EFFICACY AND SAFETY OF OBEFAZIMOD IN UC PATIENTS AT WEEKS 48 AND 96 OF AN OPEN-LABEL MAINTENANCE STUDY AMONG CLINICAL RESPONDERS AT WEEK 8 OF THE PHASE 2B INDUCTION TRIAL
Date
May 21, 2024
Obefazimod is an investigational, oral, once-daily, small molecule which enhances expression of microRNA-124 and is currently in phase 3 clinical trials for the treatment of patients with moderately to severely active ulcerative colitis (UC) [1]…
Presenter
Séverine Vermeire
Katholieke Universiteit Leuven Universitaire Ziekenhuizen Leuven
Speakers
Laurent Peyrin-Biroulet
Silvio Danese
Marla Dubinsky
Icahn School of Medicine, Mount Sinai
Parambir Dulai
Northwestern University Feinberg School of Medicine
Herbert Tilg
Britta Siegmund
Charité - Universitätsmedizin Berlin
Paul Gineste
Sheldon Sloan
Christopher Rabbat
Bruce Sands